ОСОБЕННОСТИ ТЕЧЕНИЯ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ ПРИ COVID-19

1. Huang C., Wang Y., Li X. et al. Сlinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, vol. 395, pp. 497‒506. doi: 10.1016/S0140-6736(20)30183-5. 2. Inciardi R.M., Lupi L., Zaccone G. et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol., 2020, Mar 27. doi: 10.1001/jamacardio.2020.1096. 3. Kochi A.N., Tagliari A.P., Forleo G.B. et al. Cardiac and arrhythmic complications in patients with COVID-19. J. Cardiovasc. Electrophysiol., 2020, vol. 31, no. 5, pp. 1003‒1008. doi: 10.1111/jce.14479. 4. Kwong J.C., Schwartz K.L., Campitelli M.A. et al. Acute myocardial infarction after laboratory‒confirmed influenza infection. N. Engl. J. Med., 2018, vol. 378, no. 4, pp. 345‒353. doi: 10.1056/NEJMoa1702090.PMID: 29365305. 5. Li B., Yang J., Zhao F. et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin. Res. Cardiol., 2020, vol. 109, no. 5, pp. 531‒538. doi: 10.1007/s00392-020-01626-9. 6. Long B., Brady W.J., Koyfman A. et al. Cardiovascular complications in COVID-19. Am. J. Emerg. Med., 2020, Apr. 18, pp. 1‒4. doi: 10.1016/j. ajem.2020.04.048. 7. Mehra M.R., Desai S.S., Ruschitzka F. et al. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet, 2020, Published Online May 22. doi: https://doi. org/10.1016/S0140-6736(20)31180-6. 8. Niu L., An X.J., Tian J. et al. 124 cases of clinical analysis of children with viral myocarditis. Eur. Rev. Med. Pharmacol. Sci., 2015, vol. 19, no. 15, pp. 2856‒2859. PMID: 26241540. 9. Oudit G.Y., Kassiri Z., Jiang C. et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur. J. Clin. Invest., 2009, vol. 39, no. 7, pp. 618‒25. doi: 10.1111/j.1365‒2362.200 9.02153.x. 10. Guo T., Fan Y., Chen M. et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol., 2020, vol. 27, pp. e201017. doi: 10.1001/jamacardio.2020.1017. 14. Gurwitz D. Angiotensin receptor blokers as tentative SARS-CoV-2. Therapeutic Drug. Dev. Res., 2020, Mar 4; 10.1002/ddr.21656. doi: 10.1002/ddr.21656. URL: researchgate.net. 11. Ruan Q., Yang K., Wang W. et al. Correction to: Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intens. Care Med., 2020, vol. 6, pp. 1‒4. doi: 10.1007/s00134-020-06028-z. 12. Shi S., Qin M., Shen B. et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol., 2020, vol. 25, pp. e200950. doi: 10.1001/jamacardio.2020.0950. 13. Wang D., Hu B., Hu C. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 2020, vol. 323, no. 11, pp. 1061‒1069. doi: 10.1001/jama.2020.1585. 14. Welt F.G.P., Shah P.B., Aronow H.D. et al. American College of Cardiology’s Interventional Council and the Society for Cardiovascular Angiography and Interventions. Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic: From the ACC's Interventional Council and SCAI. J. Am. Coll. Cardiol., 2020, vol. 75, no. 18, pp. 2372‒2375. doi: 10.1016/j.jacc.2020.03.021. 15. Williams B., Zhang Y. Hypertension, rennin-angiotensin-aldosterone system inhibition, and COVID-19 // Lancet. ‒ 2020. ‒ May 18. DOI:10.1016/s0140-6736(20)31131-4.